Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa Study of Tafasitamab in Relapsed/Refractory B-Cell NHL
NCT01685008Phase 2Completed
- Sponsor
- MorphoSys AG
- Start
- Apr 2013
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of tafasitamab in follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Indolent Non-Hodgkin Lymphoma (INHL), sponsored by MorphoSys AG. Started Apr 2013; status: completed.
02
Drugs
tafasitamab
03
Conditions
follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT01685008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01685008.